United Therapeutics Advances Ralinepag Study for PAH Treatment

United Therapeutics Corp. ((UTHR)) announced an update on their ongoing clinical study.

United Therapeutics Corp. is conducting a Phase 3 study titled ‘A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)’. The study aims to assess the long-term safety and efficacy of Ralinepag, a drug designed to treat PAH, a serious cardiovascular condition.

The intervention being tested is Ralinepag, an experimental drug administered as once-daily extended-release tablets. The goal is to titrate the dosage to the highest level tolerated by patients, aiming to manage symptoms of PAH effectively.

This study follows an interventional, single-group design with no masking, focusing on treatment as its primary purpose. Participants are invited from previous Phase 2 or 3 studies of Ralinepag, ensuring continuity in evaluating the drug’s effects.

The study began on September 19, 2018, and is currently enrolling by invitation. The latest update was submitted on April 17, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s development and potential market entry.

The continuation of this study could positively influence United Therapeutics’ stock performance by reinforcing investor confidence in the company’s pipeline. As PAH is a competitive field, advancements in Ralinepag’s development could position United Therapeutics favorably against competitors.

The study is ongoing, with further details available on the ClinicalTrials portal.